Biotechnology company, OSE Immunotherapeutics, has received a grant through the Eurostars European Programme, led by Bpifrance, aimed at the development of rapidly marketable innovative products, processes and services.
Euros
The project will be conducted by a European consortium of five partners and will clinically validate and analyse a platform of immune repertoire sequencing-data (T-cell receptors) with the goal of generating an immune fingerprint specific to Tedopi.
“We warmly thank Bpifrance for supporting us with this European grant and are pleased to collaborate with such a respected group of partners,” said Alexis Peyroles, CEO of OSE Immunotherapeutics. “We look forward to validating an immune algorithm specific to Tedopi and establishing precision medicine targeting for our product.”
The grant of €435,000 will be used to support translational research — to be conducted in conjunction with the Phase II clinical trial for Tedopi in pancreatic cancer, combined with a PD-1 checkpoint inhibitor. Using bioinformatics algorithms of T-cell receptors, researchers will look to generate an immune fingerprint specific to Tedopi.
It is anticipated that the Phase II study, which will be sponsored by the oncology cooperative group GERCOR as part of the PRODIGE intergroup, will start later on this year.